|
| 生物医药上市企业创新效率及影响因素研究 |
| Research on innovation efficiency and influencing factors of listed biomedical Enterprises |
| 投稿时间：2021-12-01 修订日期：2021-12-23 |
| DOI： |
| 中文关键词: 生物医药上市企业 创新效率 DEA-Malmquist指数模型 Tobit回归 |
| English Keywords:Listed biomedical Enterprises Innovation efficiency DEA-Malmquist index model Tobit regression |
| Fund Project: |
|
| 摘要点击次数: 224 |
| 全文下载次数: 0 |
| 中文摘要: |
| 文章运用DEA-Malmquist-Tobit模型对生物医药上市企业创新效率及影响因素进行分析。研究发现：创新效率整体呈现波动下降趋势,且不同所有权性质企业创新效率存在差异性；创新效率进步主要得益于技术效率变化指数的增长；技术进步下降是制约生物医药企业创新效率提升的主要因素；纯技术效率下降是制约生物医药企业创新效率提升的另一因素；政府支持、企业规模及税收负担均能显著影响生物医药上市企业创新效率。应制定合理的财税政策以进一步提升生物医药上市企业的创新效率。 |
| English Summary: |
| This paper uses DEA-Malmquist index model to measure the innovation efficiency of biomedical listed enterprises, and further uses Tobit regression to explore the influencing factors of innovation efficiency of biomedical enterprises. It is found that the innovation efficiency fluctuates and decreases as a whole, and there are differences in the innovation efficiency of enterprises with different ownership properties; The improvement of innovation efficiency mainly benefits from the increase of technical efficiency change index; The decline of technological progress is the main factor restricting the improvement of innovation efficiency of biomedical enterprises; The decline of pure technical efficiency is another factor restricting the improvement of innovation efficiency of biomedical enterprises; Government support, enterprise size and tax burden can significantly affect the innovation efficiency of biomedical listed enterprises. We should formulate reasonable fiscal and tax policies to further improve the innovation efficiency of biomedical listed enterprises. |
| 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |